NCT04430842View on ClinicalTrials.gov

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

September 21, 2022

Study Completion Date

December 22, 2022

Conditions
AstrocytomaBrain CancerBrain MetastasesBladder CancerBreast CancerCervical CancerCholangiocarcinomaColorectal CancerEsophagus CancerGastric CancerHead and Neck CancerKidney CancerLiver CancerLung CancerMelanomaOvarian CancerPancreatic CancerPleural MesotheliomaProstate CancerSarcomaTongue CancerThymic CarcinomaUrinary Tract Cancer
Interventions
DRUG

QBS10072S

QBS10072S targets cancers with high LAT1 expression.

Trial Locations (2)

2170

Sydney Southwest Private Hospital, Liverpool

2217

St George Private Hospital, Kogarah

All Listed Sponsors
collaborator

Novotech (Australia) Pty Limited

INDUSTRY

lead

Quadriga Biosciences, Inc.

INDUSTRY

NCT04430842 - Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Biotech Hunter | Biotech Hunter